Overview

A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Center, Japan

Collaborators:

Fiverings Co., Ltd.
Ono Pharmaceutical Co. Ltd

Treatments:

Cisplatin
Docetaxel
Fluorouracil
Nivolumab